by | Mar 10, 2022 | DiPersio, John, Persaud, Stephen "Steve"
— Technology Description
Researchers at Washington University in St. Louis have developed an improved process for conditioning patients for allogeneic hematopoietic stem cell transplantation (alloHSCT) using JAK inhibitors. Commonly used to treat autoimmune diseases like rheumatoid arthritis, JAK inh…
by | Mar 10, 2022 | Kremer, Jeff, Lange, Sara, Van Tine, Brian
— Background: Synovial sarcoma is a rare soft tissue sarcoma that most commonly affects young adults. Like many other cancers, there are currently no targeted chemotherapies for synovial sarcoma. Current treatment often consists of a combination of surgery, radiation therapy, and chemotherapy. The met…
by | Mar 9, 2022 | Alhallak, Kinan, Azab, Abdel Kareem
— Disease indication – multiple myeloma
Drug format – antibodies conjugated to nanoparticles for T-cell immunotherapy
Drug class – improved delivery platform
Research stage and Preliminary data:
In vivo:
In vitro proof of concept – in a MM cell line: NanoMuTEs and NanoTC…
by | Mar 3, 2022 | Yablonskiy, Dmitriy, Zhao, Yue
— Technology Description
Researchers in Prof. Dmitriy Yablonskiy’s laboratory have developed patented neuroimaging techniques to identify pre-clinical and early stage Alzheimer’s disease (AD) using MRI-based biomarkers of amyloid accumulation and other pathological changes in the brain. …
by | Mar 2, 2022 | Lim, Kian-Huat, Liu, Yongjian, Zhang, Xiaohui
— Disease indication –
Drug format – Combination containing radiolabeled copper nanocluster, small molecule, and peptide
Drug class – First-in-class
Target – CCR2, the receptor for CCL2
Mode of action – The ECL1i peptide is conjugated to a copper nanocluster loaded…